KOLINPHARMA S.p.A

KOLINPHARMA

E-commerce

I prodotti Kolinpharma

News
News from the world KOLINPHARMA

20/12/2024 - published at 11.44

KOLINPHARMA® INCLUDED AMONG THE 100 ITALIAN EXCELLENCES

A prestigious recognition for the company

22/05/2024 - published at 15.29

KOLINPHARMA®: new patent in China for Doltendix®

KOLINPHARMA® achieved the first patent in China for Doltendix®

29/03/2024 - published at 15.36

KOLINPHARMA^®: has received the prize Credit Reputation Award

20/03/2024 - published at 15.27

KOLINPHARMA^® expands the range of products with the launch of Kymax^®

In recent decades, world demographics have changed significantly with a progressive aging of the global population.

10/01/2024 - published at 14.45

Kolinpharma® launches KIPFeR® following agreement with Nemysis LTD

Kipfer is the new dietary supplement designed for all situations in which the body is deficient in iron.

06/03/2023 - published at 15.15

Kolinpharma^® for gender equity a PMIHeroes

Rita Paola Petrelli was being a guest on the podcast PMIHeroes in Ifis Bank

23/11/2022 - published at 15.34

KOLINPHARMA^®: has achieved the award as “Leader of growth 2023” for the fifth consecutive year

Even this year the company is one between 500 Italian enterprises that they were distinguished for the major growth of turnover

05/08/2021 - published at 16.06

Kolinpharma^® at VITAFOODS Europe 2021 in Geneva and at CPHI Worldwide 2021 in Milan

KOLINPHARMA^® strengthens its marketing and brand awareness strategy

26/08/2020 - published at 14.14

KOLINPHARMA^® expands its product portfolio with IVUXUR^® TABLETS.

KOLINPHARMA^® presents the new product IVUXUR^® TABLETS, which is added to the other 9 patented or patent pending products

16/04/2020 - published at 14.49

KOLINPHARMA^®:first patent for XINEPA^® in Israel and fifth outside Italy

Xinepa^® is a nutraceutical product already in possession of a double patent in Italy

31/03/2020 - published at 11.48

KOLINPHARMA^® donates a pulmonary ventilator for the hospitals of city of catanzaro to fight COVID 19

KOLINPHARMA^® supports physicians and health professionals by becoming a partner in the fundraising initiative "Politeama Foundation

10/03/2020 - published at 16.45

KOLINPHARMA^® obtains the patent in the U.S. of Dolatrox^®

It is the fourth patent that is added to Ivuxur^® and to the 2 of Xinepa^®

24/05/2019 - published at 10.54

KOLINPHARMA^® invests in product quality and safety

Strict product controls guarantee quality and safety for the consumer.

05/02/2018 - published at 09.48

The scientific medical information: an extraordinary job, because it is ethical, scientific and it empathizes with the doctor

KOLINPHARMA always took care about the selection of its collaborators.

05/02/2018 - published at 09.53

Functional Growth: the policy of “internal growth”

KOLINPHARMA wants to give functional growth opportunities to its own collaborators

05/02/2018 - published at 09.58

Marketing: a specific science which studies the market

Kolinpharma completed the company organization, including a Junior Product Manager

09/01/2018 - published at 12.16

KOLINPHARMA^® in the European research

Since 2017, the company faced an international research.

02/01/2018 - published at 12.15

KOLINPHARMA^® chooses Hoffmann & Eitle Italia as partner

One of the biggest European law firm specialized in patents, models and design and of all internation industrial protection rights.

02/01/2018 - published at 10.24

A quoted company at AIM, as depositary and logistic: Bomi Group

KOLINPHARMA gave to BOMI Group the storage and the transport of its products to distributors.

02/01/2018 - published at 10.28

Research and Development team (R&D): effectiveness and innovation

The company’s beating heart, the R&D team, is part of the company.

29/12/2017 - published at 10.33

The 231, a model which commit us everyday

All the direct and indirect staff, firm the Company Ethical Code, with consciousness and commitment about what it is necessary follow.

22/12/2016 - published at 14.16

2016: KOLINPHARMA^® revenue redoubles!

The effort of all, from company heart to sales network, has enabled us to reach the target set at the begin of the year: the revenue doubling, touched 2,5 million in 2016.

Media

Almetax Easy and tablets

Certified products

Company validations

Consumer Protection

Corporate compliance

Profile and organization

Research and development

Respect the environment

Xinepa Easy and tablets

Contact media relations

“Science accuracy and listen to people”

“Science accuracy and listen to people”